AparnaB Dixit

Blood-based biomarkers in Alzheimer's and Parkinson's disease: From molecular pathology to therapeutic potential.

This chapter highlights a overview of blood-based biomarkers emerging in the field of AD and PD, exploring the clinical utility of core pathology markers (Aβ42/40, p-tau species, and α-synuclein), alongside other neurodegenerative markers such as neurofilament light chain and glial activation markers like GFAP.

Brain lipid dysregulation as a driver of energy metabolism failure in Alzheimer's disease.

ACK family tyrosine kinases as potential therapeutic targets for cancer.

INTRODUCTION The Activated Cdc42-associated kinase (ACK) family, comprising TNK1 and ACK1/TNK2 are critical regulators of oncogenic signaling and epigenetic reprogramming. Their unique structural architecture, including ubiquitin-association domain, sterile alpha motif domain and Mig6 homology regions, distinguishes th...

Metabolic dysregulation in Alzheimer's disease: Mechanisms, markers, and therapeutic prospects.